Neuroscience Trials Australia (NTA) was established in 2001 as the clinical trials platform of the National Neuroscience Facility (NNF) with the primary aim to build in Australia a world-class infrastructure for neuroscience clinical trials. Governed by a Management Board made up of leading clinicians representing the various disease interest groups across the neurosciences, NTA plays a key role in the translation of quality research into clinical practice, resulting in better health outcomes for the Australian public.

Chaired by Professors Stephen Davis and Geoffrey Donnan, and located within their respective institutions, NTA is one of eight synergistic neuroservice platforms that make up the National Neuroscience Facility (NNF). The NNF is an Australia-wide collaboration of neuroscience research institutes and provides access to infrastructure services and expertise.

Our vision is a world where neurological conditions are understood, remedies discovered, and cures achieved.

Our Mission is to bring together talented people to tackle and in time defeat the many facets of neurological disorders.

NTA was established to support the existing and emerging disease specific clinical trial interest groups in the neurosciences, to provide support and services to formalise those networks and to facilitate interactions with industry sponsors of clinical research. Clinical investigators may access NTA services via the disease specific interest groups, each with their own membership rules and regulations. Industry sponsors of clinical trials may access NTA services directly.